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Background: Anaplastic lymphoma kinase (ALK)-rearranged non–
small-cell lung cancer (NSCLC) is markedly sensitive to the ALK 
inhibitor crizotinib. However, acquired resistance to crizotinib is inevi-
table through several mechanisms. Therefore, this study was conducted 
to identify genetic alterations associated with crizotinib resistance.
Methods: Tumor samples were derived from seven ALK-positive 
NSCLC patients who showed acquired resistance to crizotinib, and 
these patients were analyzed for ALK, EGFR, and KRAS mutations 
and ALK and EGFR gene amplifications. In vitro cytotoxicity of 
crizotinib and ALK downstream signals were compared between 
crizotinib-naive and -resistant NSCLC cells.
Results: After a median duration of 6 months (range, 4–12 months), 
seven ALK-positive NSCLC patients developed acquired resistance to 
crizotinib. Three patients harbored secondary ALK mutations, includ-
ing one patient with both mutations: L1196M (n = 2) and G1269A 
(n = 2). Of note, one patient displayed ALK gene copy number gain 
(4.1-fold increase compared with the pre-crizotinib specimen) and 
EGFR L858R mutation with high polysomy. The amphiregulin con-
centration was high in the supernatant fluid from five patients with 
malignant pleural effusion (116.4–18934.0 pg/ml). SNU-2535 cells 
derived from a patient who harbored the G1269 mutation were resis-
tant to crizotinib treatment similar to H3122 CR1 cells. L1196M and 
G1269A mutant clones were less sensitive to crizotinib and ALK 
downstream signals were ineffectively suppressed in these clones.
Conclusions: Genetic changes associated with crizotinib resistance 
are heterogeneous in ALK-rearranged NSCLC patients who respond 
to crizotinib and subsequently develop resistance.
Key Words: Anaplastic lymphoma kinase, Non–small-cell lung can-
cer, Crizotinib, Acquired resistance, ALK mutation.
(J Thorac Oncol. 2013;8: 415-422)
Anaplastic lymphoma kinase (ALK) has been identified as the fusion partner of echinoderm microtubule-associated 
protein-like 4 (EML4) in non–small-cell lung cancer (NSCLC), 
and this fusion accounts for 3.0 to 6.7% of NSCLC patients.1,2 
Despite various fusion variants2 and partners, including TRK-
fused gene3 and kinesin family member 5B (KIF5B),4,5 the com-
plete intracellular portion of ALK is preserved and oncogenic. 
In vitro and in vivo sensitivities to ALK tyrosine kinase inhibi-
tors6 were translated into clinical activities of crizotinib, a dual 
inhibitor of ALK and c-MET against ALK-positive NSCLC.7 A 
recent phase I trial of crizotinib resulted in an objective response 
rate of 57%, a disease control rate of 87% at 8 weeks, and a 
median progression-free survival of 10 months.7,8 In addition, 
a first-line phase III trial comparing crizotinib and pemetrexed 
plus cisplatin is currently ongoing in ALK-rearranged NSCLC 
patients (NCT01154140). Although ALK-rearranged NSCLC 
was shown to be highly susceptible to crizotinib treatment,7 a 
fraction of tumors eventually became resistant to crizotinib.9 
In line with the T790M “gatekeeper” mutation in epidermal 
growth factor receptor (EGFR)-mutant NSCLC,10 L1196M in 
the ALK gatekeeper site was identified in a Japanese patient who 
showed acquired resistance to crizotinib.9 In addition, nongate-
keeper mutations such as L1152R,11 C1156Y,9 and G1269A,12 
and alternative pathway activation, including ligand-depen-
dent EGFR activation,11 EGFR mutation,12 or amplification,13 
were suggested to be resistance mechanisms in ALK-positive 
NSCLC treated with ALK inhibitors.
Here, we evaluated heterogeneous genetic changes 
associated with crizotinib resistance in seven ALK-rearranged 
NSCLC patients who initially responded and eventually 
showed resistance to crizotinib.
PATIENTS AND METHODS
Patients
Crizotinib at a dosage of 250 mg twice daily was admin-
istered to seven patients with ALK-rearranged NSCLC, of 
whom four were enrolled into phase I (NCT00585195) trial7 
and two were enrolled in phase II (NCT00932451) trial. All 
were diagnosed with stage IV NSCLC disease, and most 
patients received crizotinib as second-line treatment and 
beyond (Table 1). Response evaluation was based on the 
Response Evaluation Criteria in Solid Tumors version 1.0 per 
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protocol.14 Tumor tissues were obtained in patients who failed 
crizotinib and provided informed consent. This study was 
approved by the Institutional Review Board of Seoul National 
University Hospital (H-1205-126-411).
Molecular Determinations of ALK, 
EGFR, and KRAS and Measurement 
of EGFR Ligand Levels
ALK fluorescence in situ hybridization (FISH) was 
analyzed using an ALK probe (Vysis LSI ALK dual-color, 
break-apart rearrangement probe; Abbott Molecular, Des 
Plaines, IL) in formalin-fixed and paraffin-embedded tissues 
or cell pellets derived from malignant pleural effusions. ALK 
FISH was considered positive when break-apart signals were 
observed in more than 15% of 50 or more analyzed cells.7,15 
In addition, the number of copies per cell of the ALK gene 
rearrangement was determined before and after crizotinib, 
and ALK gene amplification was defined as a greater than 
twofold increase of the mean of the rearranged gene per cell 
in the post-crizotinib specimen compared with the precrizo-
tinib specimen.12 EGFR amplification was evaluated using an 
EGFR probe (Vysis LSI EGFR; Abbott Molecular) and EGFR 
FISH positivity was determined according to the Colorado 
scoring criteria.16 EGFR and KRAS mutations were analyzed 
using direct sequencing of extracted DNA from NSCLC 
patient tumors or cell lines.17
Amphiregulin and EGF levels were measured in the cell 
culture medium or supernatant fluid of pleural effusion using 
an enzyme-linked immunosorbent assay kit (Quantikine R&D 
Systems, Minneapolise, MN). All samples were run in at 
least duplicate. The concentrations of the EGFR ligands were 
determined by comparison with standard curves.
Cell Lines and Reagents
NCI-H3122 cells were provided by Pasi A. Jänne (Dana-
Farber Cancer Institute, Boston, MA) and NCI-H2228 cells 
were purchased from the American Type Culture Collection 
(ATCC; Manassas, VA). SNU-2535 cells were established 
at the Korean Cell Bank using pleural effusion in a patient 
who had developed acquired resistance to crizotinib (SNU4 
patient, Table 1). NCI-H3122, NCI-H2228, and SNU-2535 
cells were maintained in RPMI 1640 medium with gentamicin 
(GIBCO, Grand Island, NY) supplemented with 10% fetal 
bovine serum (GIBCO). The cell lines were incubated at 37°C 
in a humidified atmosphere of 5% carbon dioxide. Crizotinib 
was kindly provided by Pfizer (Milwaukee, WI) and dissolved 
in dimethyl sulfoxide (Sigma Aldrich, St. Louis, MO) for 
experiments. Total ALK (#3333), phosphorylated ALK Tyr 
1604 (#3341), total AKT (#4685), phosphorylated AKT 
(#4060S), total ERK p42/44 (#9102), phosphorylated ERK 
(#9106), and GAPDH (#5174) antibodies were purchased 
from Cell Signaling Technology (Danvers, MA) and were 
used for immunoblotting. The blots were washed, transferred 
to freshly prepared enhanced Lumi-Light Western Blotting 
Substrate (Roche, Indianapolis, IN), and subjected to imaging 
analysis using an LAS-3000 imaging system (Fuji Photo Film 
Co., Stamford, CT).
Reverse Transcription–Polymerase 
Chain Reaction and Genotyping
Total RNA was isolated from the NSCLC cell 
lines using an RNA Mini kit (Invitrogen, Carlsbad, CA). 
Each sample was reverse transcribed into cDNA using 
SuperScript II reverse transcriptase (Invitrogen). PCR ampli-
fication was performed using protocols with specific primers 
TABLE 1.  Clinical Characteristics of Patients with Acquired Resistance to Crizotinib
Patient No. Age Sex Histology Prior chemotherapy
Crizotinib outcomes
Lines Cycles ORR PFS, months Specimens after resistance OS, months
SNU1 45 M Adenocarcinoma GP + bevacizumab × 4 2 7 PR 6 Pleural effusions 14
GP × 6
SNU2 51 F Adenocarcinoma Gefitinib × 1 5 8 PR 5 Pleural effusions, hepatic 
lesion
30
Pemetrexed × 6
Navelbine × 6
SNU3 64 M Adenocarinoma None 1 11 PR 9 Lung lesion 28
SNU4 57 F Non-small cell GC × 2 3 13 PR 12 Pleural effusions  
(SNU-2535)
24
carcinoma, NOS Docetaxel × 7
SNU5 47 F Adenocarcinoma Pemetrexed + cisplatin × 1 2 4 PR 4 Liver lesion 12
Irinotecan + cisplatin × 6
SNU6 36 F Adenocarcinoma Erlotinib × 1 5 8 PR 6 Pleural effusions 29
Pemetrexed × 15
GN × 4
SNU7 50 M Adenocarcinoma Paclitaxel + cisplatin × 2 4 8 PR 6 Pleural effusion,hepatic 
lesion
25
Pemetrexed × 7
Gefitinib × 1
GC, gemcitabine plus carboplatin; GN, gemcitabine plus navelbine; GP, gemcitabine plus cisplatin; ORR, overall response rate; OS, overall survival; PFS, progression-free survival 
from the first administration of crizotinib until the date of objective disease progression or death from any cause; PR, partial response.
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(Supplementary Table 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A387). The images were captured 
using the Gel Logic 200 imaging system (Kodak, Rochester, 
NY). The PCR products were purified using a PCR purifica-
tion kit (Invitrogen) and a DNA concentration kit (ZYMO 
RESEARCH, Irvine, CA) and subsequently sequenced as 
described later. Genomic DNA was isolated from cell pellets 
or tissues using an ALL-prep DNA/RNA micro kit (QIAGEN, 
Valencia, CA) according to the manufacturer’s protocol. 
Exons of ALK were amplified from genomic DNA using the 
High Fidelity plus PCR system (Roche, Indianapolis, IN) 
and sequenced bi-directionally by Sanger dideoxynucleo-
tide sequencing with the primers for ALK exons 23 and 25 
(Supplementary Table 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A387). Mutation-specific PCR 
of L1196M and G1269A were performed with primer 
sequences. Direct sequence analysis was performed using an 
ABI 3730 DNA sequencer (Applied Biosystems, Carlsbad, 
CA). The reference sequences for ALK and EML4 were 
NM_004304.4 and NM_019063.3, respectively. All muta-
tions were confirmed at least twice from independent PCR 
isolates and sequence tracing was reviewed in the reverse 
direction by visual inspection.
Cloning of EML4-ALK Expression Constructs
EML4-ALK variant 1 cDNA from H3122 cells was 
amplified using primers. The PCR products were cloned 
into the TOPOTA vector (Invitrogen) and transformed into 
bacteria, and the ALK kinase domain (residues 1094–1396) 
was sequenced in individual clones. To generate EML4-ALK 
mutants, the L1196M or G1269A mutation was introduced 
using site-directed mutagenesis (Agilent Technologies, La 
Jolla, CA) with mutant-specific primers according to the 
manufacturer’s instructions. The PCR primers are listed in 
Supplementary Table 1 (Supplemental Digital Content 1, 
http://links.lww.com/JTO/A387). The sequencing products 
were analyzed using Sequencer software (Gene codes). 
The Basic Local Alignment and Search Tool (BLAST data-
base) was used to determine the identification of unknown 
sequences. Retroviral infection and culture of Ba/F3 cells 
were performed using a previously described method.1 
Polyclonal cell lines were established by puromycin selec-
tion and subsequently cultured in the absence of interleu-
kin-3. Uninfected Ba/F3 cells were used as controls.
Cell Proliferation and Apoptosis Assays
NSCLC cells at a density of 5000 cells per well in 
96-well plates were cultured in the presence of crizotinib 
or vehicle for 72 hours, and cell proliferation was ana-
lyzed using the CCK-8 colorimetric assay (Dojindo, Tokyo, 
Japan). The absorbance was measured at 450 nm in an Eon 
Microplate Spectrophotometer (BioTek, Winoosk, VT) 
using at least duplicate samples. The NSCLC cells treated 
with crizotinib or vehicle were stained with Annexin V and 
7 AAD, and then the cells were analyzed by flow cytom-
etry using a FACSCalibur instrument (Becton Dickinson, 
Franklin Lakes, NJ).
RESULTS
Patient Outcomes and the ALK 
Fusion Transcript Analysis
Treatment outcomes are described in Table 1. All patients 
achieved a partial response and subsequently experienced dis-
ease progression at a median time of 6 months (range, 4–12 
months). Although most patients discontinued crizotinib at 
the time of documented progressive disease, SNU2 patients 
received crizotinib beyond disease progression owing to 
ongoing clinical benefit. EML4-ALK fusion transcripts were 
analyzed by reverse transcription–polymerase chain reaction 
and PCR fragments that represented variable truncations of 
EML4 at exons 13 to 20 (432 base pairs) and 6 to 20 (917 base 
pairs) were sequenced. Variant 1 that fuses EML4 exon 13 to 
ALK exon 20 (E13;A20) was identified in four patients and 
variant 3 (E6;A20) was observed in two patients (Table 2 and 
Fig. 1A). One patient harbored an ALK fusion at exon 20 with 
exon 15 of KIF5B.
ALK Mutations in Crizotinib-Resistant Tumors
The G→C and C→A substitutions at nucleotides 
4713 (G1269A) and 4493 (L1196M) of ALK were iden-
tified and confirmed by Sanger sequencing. Of note, the 
SNU1 tumor harbored both L1196M (frequency, 6.59%) 
and G1269A (28.5%) mutations in separate clones (Fig. 
1B). The SNU4 patient displayed the G1269A mutation at 
a frequency of 68.75%. In addition, the L1196M mutation 
was found in SNU6 tumoral cDNA clones (27.8%). These 
were confirmed using L1196M or G1269A mutation-spe-
cific PCR (Fig. 1C). However, the remaining four patients 
demonstrated no secondary mutation within the ALK 
kinase domain. SNU-2535 derived from an SNU4 patient 
harbored the G1269A mutation (61.9%).
ALK Mutations Confer Resistance to Crizotinib
293T cells were transiently transfected with cDNA 
encoding wild-type (WT) EML4-ALK, EML4-ALK 
L1196M, or EML4-ALK G1269A to evaluate resistant 
properties of these mutations. ALK phosphorylation was less 
decreased in 293T-L1196M or -G1269A cells than in 293T-
WT cells after exposure to crizotinib in a dose-dependent 
manner (Fig. 2A). In addition, Ba/F3 cells that expressed 
secondary ALK mutations were resistant to crizotinib 
treatment compared with those expressing WT EML4-ALK 
(Fig. 2B). Apoptotic cells determined by Annexin V and 
7-AAD were higher in H3122 cells than in SNU-2353 cells 
treated with crizotinib (Fig. 2C). H3122 CR1 cells that were 
generated by an increasing dose of crizotinib to 1 μM13 and 
SNU-2535 cells were resistant to crizotinib compared with 
H3122 cells (half maximal inhibitory concentration [IC
50
], 
6.01 and 4.1 µM, respectively; Fig. 3A). Crizotinib treatment 
suppressed expression of phospho-ALK, -AKT, and -ERK 
in H3122 cells. However, crizotinib ineffectively suppressed 
phosphorylated proteins in SNU-2535 and H3122 CR1 
cells (Fig. 3B). Apoptotic cells were reduced in SNU-2535 
cells compared with those in H3122 cells after exposure to 
crizotinib (Fig. 3C).
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Heterogeneous Genetic Changes 
in Crizotinib-Resistant Tumors
Although patients with secondary ALK mutations 
showed no other genetic alteration, those without these 
mutations were tested for genetic alterations of alterna-
tive pathways (Table 2). Of note, the SNU5 patient had an 
ALK gene amplification (ALK gene copy number gain, 4.1-
fold increase compared with the precrizotinib specimen; 
Fig. 4A) and L858R mutation in EGFR exon 21 with 
EGFR high polysomy (EGFR/CEP = 1.79; Fig. 4B). She 
carried a WT EGFR gene with disomy in the initial tumor 
tissue.
TABLE 2.  Heterogeneity of Genetic Changes Associated with Crizotinib Resistance in Seven Patients with ALK-Rearranged 
NSCLC
No ALK variants
Before crizotinib After crizotinib
ALK 
FISH
EGFR 
FISH EGFR mutation KRAS mutation
ALK 
FISH ALK mutation
EGFR 
FISH EGFR mutation KRAS mutation
1 E13;A20 + WT − ND ND L1196MG1269A ND − −
2 E6;A20 + ND ND ND + WT WTa − −
3 E13;A20 + WTa − − + WT WTa − −
4 E13;A20 + ND ND ND + G1269A WTb − −
5 E13;A20 + WTb − − +d WT +c + (L858R) −
6 E6;A20 + WT − − + L1196M WTa − −
7 KIF5B;A20 + WT − − + WT WTa − −
aEGFR disomy.
bEGFR low trisomy.
cEGFR high polysomy.
dALK gene amplification.
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; ND, not done; NSCLC, non–small-cell lung cancer; WT, wild-type.
FIGURE 1.   ALK fusion transcripts and ALK mutations. (A) Virtual gel electro-phoresis was performed on multiple RT-PCR prod-
ucts derived from patients’ specimens (n = 7) and NSCLC cells (n = 3). The suffix “B” indicates tumor specimens before crizo-
tinib treatment. Four and two patients harbored EML4-ALK variants 1 and 3, respectively. The KIF5B-ALK fusion transcript was 
detected in an SNU7 patient. (B) Electropherograms showed the 4713 G→C and 4493 C→A mutations in an SNU1 patient. (C) 
L1196M and G1269A were detected by mutation-specific PCR assays. ALK, anaplastic lymphoma kinase; NSCLC, non–small-cell 
lung cancer; RT-PCR, reverse transcription–polymerase chain reaction.
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However, genetic alterations associated with acquired 
resistance to crizotinib were not found in three ALK-positive 
NSCLC patients. In addition, ALK or EGFR gene amplifi-
cation and EGFR or KRAS mutation were not observed in 
SNU-2535 cells. KRAS gene mutation was not found in all 
tumor tissues.
The amphiregulin concentration was significantly high 
in supernatant fluid from SNU1 (1894.0 pg/ml) and SNU6 
(1832.5 pg/ml) patients than the amphiregulin concentration 
in supernatant fluid from SNU2, 4, and 7 patients (116.4–
460.0 pg/ml; Fig. 4C). Similarly, SNU1 and SNU6 patients 
demonstrated relatively high EGF concentrations (Fig. 4D). 
EGFR ligand levels were significantly high in SNU-2535 and 
H3122 CR1 cells than in H3122 cells.
DISCUSSION
Our study demonstrates that acquired resistance mecha-
nisms are heterogeneous in ALK-rearranged NSCLC treated 
with crizotinib. Three of seven patients (43%) had secondary 
ALK mutations and one patient (14%) showed a high ALK 
gene copy number and activation of EGFR signals expressed 
by high EGFR polysomy and L858R in EGFR exon 21. In 
addition, five patients with malignant pleural effusions showed 
a high concentration of amphiregulin.
L1196M is a “gatekeeper” mutation in ALK, which is 
analogous to T315I in ABL and T790M in EGFR, and steri-
cally interferes with crizotinib binding.9 This confers a high 
level of resistance to crizotinib with an IC
50
 of 1000 nM or 
more and is identified even at the highest dose of crizotinib 
in in vitro mutagenesis screening.7,18 Recently, six patients 
with ALK-rearranged NSCLC who received crizotinib 
harbored L1196M mutation after a median duration of 6 
months (range, 4–28 months), including two patients in this 
study.9,12,19 The insensitivity of L1196M clones to crizotinib 
and ineffective suppression of phospho-ALK was confirmed 
in our Ba/F3 and 293T systems, similar to previous stud-
ies.9,11–13,19 Mutation at position G1269 in the DFG motif 
was identified by in vitro mutagenesis18 and in two patients 
who showed acquired resistance to crizotinib.12 G1269A 
mediated an intermediate resistance between C1156Y and 
L1196M,12 a finding that was similarly observed in our 
analysis. Currently, four patients with ALK-positive NSCLC 
received crizotinib for a median duration of 9 months (range, 
6–13 months) until disease progression with G1269A acqui-
sition.12 Of note, one patient had both L1196M and G1269A 
mutations that were confirmed by a highly sensitive muta-
tion-specific PCR assay in different clones, findings similar 
to those in a case report,9 suggesting heterogeneous tumor 
clones under a different pressure within the same patient. 
We found no ALK secondary mutation such as 1151Tins,19 
L1152R,11 C1156Y,9 F1174C,20 G1202R,19 D1203N,20 or 
S1206Y19 in our patients. However, because of unknown 
results of L1196M and G1269A in tumors before crizotinib, 
we do not know truly gained secondary ALK mutations in 
SNU1, 4, and 6 patients.
ALK copy number gain was observed in partially 
resistant H3122 cells, resulting in a step-wise evolution of 
acquired resistance to crizotinib.13 This was confirmed in three 
patients, of whom one had a G1269A mutation,12,19 and in our 
patient. Of note, our patient with ALK gene amplification 
harbored EGFR mutation (L858R) and EGFR high polysomy. 
She had no detectable EGFR mutation by direct sequencing 
before crizotinib and her tumor responded to crizotinib only 
for 4 months. Thus far, two patients have co-existent ALK 
dominant and nondominant mechanisms of resistance: one 
patient harbors G1202R mutation and KIT amplification,19 
whereas the other patient displayed ALK copy number gain 
FIGURE 2.   L1196M and G1269A mutant clones 
are resistant to crizotinib treatment. (A) 293T cells 
transiently transfected with EML4-ALK WT, L1196M, 
and G1269A constructs showed ineffective suppres-
sion of phospho-ALK in crizotinib-resistant clones. 
(B) Ba/F3 cells were transformed to express wild-
type EML4-ALK or EML4-ALK harboring L1196M or 
G1269A mutations. The parental Ba/F3 cells with 
IL-3 or the EML4-ALK-expressing Ba/F3 cells without 
IL-3 were treated with crizotinib. Cell cytotoxicity 
was measured using CCK-8. The IC50 values were 
14.874, 0.049, 0.216, and 0.482 µM in Ba/F3+IL3, 
Ba/F3-WT, Ba/F3-L1196M, and Ba/F3-G1269A cells, 
respectively. ALK, anaplastic lymphoma kinase; IL, 
interleukin.
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and EGFR mutation with high polysomy. These findings 
suggest heterogeneous resistance mechanisms associated 
with crizotinib treatment even in the same patient with 
ALK-rearranged NSCLC.
ALK nondominant mechanisms of resistance consist 
of second oncogene activation with partial ALK dependence 
and separate oncogene activation with ALK independence.20 
The former includes ligand-dependent EGFR11 or KIT19 acti-
vation; and the latter includes KRAS or EGFR mutation.12 Of 
note, five patients with malignant pleural effusions at the time 
of crizotinib resistance had high amphiregulin concentration 
in supernatant fluid, suggesting ligand-dependent EGFR 
activation. However, unknown results of EGFR ligands in 
pre-crizotinib samples and EGFR phosphorylation in tumors 
might weaken the possible resistance mechanism associated 
with EGFR signals.
In conclusion, genetic changes associated with acquired 
crizotinib resistance are heterogeneous in ALK-rearranged 
NSCLC in our study. Despite a small number of patients 
and preexistent similar studies, it is hoped that demonstrated 
high concentrations of EGFR ligands in patients’ samples 
and identified one patient with both ALK dominant and 
nondominant mechanisms of crizotinib resistance. Although 
we successfully identified ALK dominant and nondominant 
resistance mechanisms in four (57%) and one (14%) of 
seven patients, respectively, these were not observed in 
three patients. Therefore, a new technique such as next-
generation sequencing is necessary to uncover a novel 
mechanism associated with crizotinib resistance. In addition, 
identification of resistant mechanisms might help to select 
a patient who benefits from new ALK-directed therapies: 
new agents such as an HSP90 inhibitor, or a combination of 
crizotinib and a new agent.
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FIGURE 3.   ALK mutant NSCLC cells are resistant to crizotinib treatment. (A) A cell viability assay was plotted for H3122, 
SNU-2535, and H3122 CR1 cells (crizotinib-resistant) treated with or without crizotinib for 72 hours. (B) Phospho-ALK down-
stream signals were less suppressed after treatment with crizotinib in SNU-2535 and H3122 CR1 cells than in H3122 cells. (C) 
Apoptosis induction was high in H3122 cells compared with that in SNU-2535 cells treated with crizotinib. ALK, anaplastic 
lymphoma kinase; NSCLC, non–small-cell lung cancer.
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